Aditya Bardia, MD, MPH briefly explains metastatic ER+/HER2- breast cancer, and reviews existing treatment options for patients with ER+/HER2- mBC.
Potential Role of Elacestrant for the Treatment of Metastatic ER+/HER2- Breast Cancer
Dr Bardia talks about the role of biomarker testing and provides an overview of factors which may contribute to a clinician’s choice of treatment strategy for patients with ER+/HER- mBC.
Dr Bardia discusses the mechanism of action of elacestrant, how elacestrant compares to other SERDS, and introduces the EMERALD trial.
Taking a closer look at the EMERALD trial, Dr Bardia shares key efficacy outcomes from the sub-group analyses 1) of patients with no prior chemotherapy and 2) comparing elacestrant to fulvestrant or AI.
Dr Bardia provides his opinion on the current state of the ER+/HER2- treatment landscape and where elacestrant belongs in the current treatment paradigm.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
